Using this assay can drastically improve the future growth and reputation of a biobanking or discovery organization. The performance of our MxP® Quality Control Plasma assay has been validated and has sparked the interest of the industry.
Berlin, Germany (PRWEB) April 15, 2015
In order to understand the mechanism behind the progression of a disease, and consequently discover the drugs necessary to combat a disease, researchers depend on the availability of high quality sample materials (e.g., blood plasma, blood serum, urine, organ tissue). Increasingly, it has been reported that there are issues with the reliability and consistency of samples, based on whether they have been collected and stored properly, or they have degraded for various pre-analytical reasons. Therefore, to improve the reliability of scientific studies, there is a need for samples to be tested to ensure they are of high-quality, and have been sufficiently well-annotated to support good scientific rigor.
It is now possible to detect pre-analytical variation in sample materials using biomarkers as the quality control mechanism. To investigate this urgent need, and to offer a viable solution, Metanomics Health GmbH has launched an “industry first” white paper entitled: The Benefits of Metabolomics-Based Quality Control of Human Plasma Samples for Clinical Biobanking.
With the explosion in the number of samples being deposited, academic and commercial biobanks play a crucial role in today’s biomedical research and clinical trials. This white paper explores the current state of quality control of biobank specimens in clinical R&D, and examines how metabolomics-based assays can provide increased quality control. With the information in this white paper, the goal is to produce an increased chance of successful drug targets and biomarker identification, along with validation and the delivery of reproducible data.
MxP® Quality Control Plasma is the only quality control assay that provides information about the presence of pre-analytical deviations. This is accomplished by using the company’s unique algorithms to measure multiple metabolic biomarkers. The assay also provides recommendations on the sample usage.
“Using this assay can drastically improve the future growth and reputation of a biobanking or discovery organization”, said Beate Kamlage, Senior Scientist, Data Interpretation Health, Metanomics Health GmbH. “The performance of our MxP® Quality Control Plasma assay has been validated and has sparked the interest of the industry. This white paper outlines important information to inform the decision-making process for the biobanking industry.”
Metanomics Health is internationally acclaimed as a pioneer in the development of many complex technical processes involved in metabolite profiling. These different techniques allow for a multitude of applications. Born from their pioneering work, the new MxP® Quality Control Plasma assay, used to assess sample quality, is an innovative and one-of-a-kind solution in the clinical biobanking industry.
For more information on MxP® Quality Control Plasma assay, or to request a copy of the white paper, please send an email to info(at)metanomics-health(dot)com
About Metanomics Health GmbH – a BASF Group Company
Metanomics Health GmbH is a BASF Group company based in Berlin, Germany.
The company believes in global reach and local presence with additional offices in Research Triangle Park, North Carolina, USA and in Tokyo, Japan serving a wide range of partners and customers worldwide.
With more than 160 experts embedded in the powerful global BASF network, Metanomics Health provides highly robust and reproducible analysis of metabolite pathways and their changes in response to disease, pharmaceutical intervention, and nutrition.
The company’s cutting-edge technology includes state-of-the-art statistics, proprietary bioinformatics tools and biomedical expert interpretation of high quality data sets. Metanomics Health provides unique information about mechanisms of action, new drug targets and predictive drug safety. These decision-enabling biomedical data accelerate drug development by reducing risk, increasing efficacy, and helping to identify therapy responders.
Metanomics Health GmbH
Tegeler Weg 33
Phone: +49 30 34807-400
Fax: +49 30 34807-401